Pharmacy Medical News about Acute Coronary Syndrome Percutaneous coronary intervention prasugrel clopidogrel

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Vascular Health and Risk Management, 10/22/09

Norgard NB et al. – Clopidogrel, when added to aspirin, has demonstrated considerable success at reducing thrombotic complications of ACS and/or PCI compared to aspirin alone and is standard of care for the management of patients with ACS and in patients undergoing PCI. Prasugrel is a novel thienopyridine antiplatelet agent recently approved for the treatment of patients with ACS undergoing PCI. Prasugrel provides greater and more consistent platelet inhibition than clopidogrel due to earlier and more extensive formation of its active metabolite. The enhanced platelet inhibition with prasugrel led to a reduction in major adverse cardiovascular events in patients with moderate to high risk ACS scheduled for PCI in the phase 3 TRITON–TIMI 38 trial. This benefit was seen more in patients suffering a STEMI and those with diabetes. However, this reduction in events was met with a significant increase in the risk of bleeding which overcame prasugrel’s benefit in certain groups.

<< Previous
Has Pay-for-Performance Decreased Access for Minority Patients

Next >>
S-Adenosylmethionine for osteoarthritis of the knee or hip

Dual antiplatelet therapy in coronary artery disease: A case-based approach
Cleveland Clinic Journal of Medicine, 11/04/09 Relevance Score: 99%

Ticagrelor demonstrated greater efficacy over clopidogrel in the most urgent clinical setting: Patients with ST-Segment Elevation Myocardial Infarction and planned Percutaneous Coronary Intervention
AstraZeneca, 11/16/09 Relevance Score: 98%

Predictive Values of Post-Treatment Adenosine Diphosphate–Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients
The American Journal of Cardiology, 10/15/09 Relevance Score: 98%

Acute Coronary Syndromes: Diagnosis and Management, Part II
Mayo Clinic Proceedings, 11/03/09 Relevance Score: 97%

Management of Spontaneous Coronary Artery Dissection: Review of the Literature and Discussion Based on a Series of 12 Young Women with Acute Coronary Syndrome
Cardiology, 10/12/09 Relevance Score: 97%